Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 20.33B P/E - EPS this Y 35.00% Ern Qtrly Grth -
Income -523.7M Forward P/E -20.19 EPS next Y 76.30% 50D Avg Chg -7.00%
Sales 3.1B PEG -0.15 EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 5.23 EPS next 5Y 277.20% 52W High Chg -32.00%
Recommedations 1.80 Quick Ratio 1.64 Shares Outstanding 97.25M 52W Low Chg 52.00%
Insider Own 19.51% ROA -9.69% Shares Float 560.24M Beta 0.61
Inst Own 49.47% ROE -14.62% Shares Shorted/Prior 2M/2.01M Price 189.77
Gross Margin 84.98% Profit Margin -16.91% Avg. Volume 231,861 Target Price 274.60
Oper. Margin -11.53% Earnings Date Nov 7 Volume 562,730 Change -8.12%
About BeiGene, Ltd.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene, Ltd. News
12/12/24 BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
12/09/24 BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
12/04/24 BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
12/03/24 BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target
12/02/24 Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now?
12/02/24 BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
11/27/24 BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment
11/27/24 Why Is BeiGene Stock Trading Higher On Wednesday?
11/27/24 European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
11/26/24 BeiGene to Present at Upcoming Investor Conferences
11/25/24 High Growth Tech Stocks to Watch in November 2024
11/19/24 Labcorp CFO Glenn Eisenberg Announces Plans to Retire
11/19/24 BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
11/15/24 BeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy Now
11/15/24 Halozyme bids for Evotec; BeiGene gets a new name
11/14/24 BeiGene Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/14/24 BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
11/13/24 Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight
11/12/24 BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
11/06/24 BeiGene to Present at the Jefferies London Healthcare Conference
BGNE Chatroom

User Image Javier_Bryan Posted - 1 day ago

$BGNE $UTHR 🔥 MYNZ 86% in 2 days move! FDA fast-track soon Petra’s Hint on X, 88% accuracy (unlike EXAS 42 % \ GH 20%), strong partners (DGX, TMO). $50-$100 target by Q2 2025. 🚀

User Image ThisIsBiotech Posted - 1 day ago

$LPTX $MRK $LLY $BGNE $GILD I completely agree with the bullish outlook. $LPTX’s DKN-01 seems poised to revolutionize the gastric/GEJ cancer treatment landscape. The ability to address the 2/3 cases where PD-1 inhibitors fail, while simultaneously boosting efficacy in the remaining 1/3 cases, positions this therapy as a game-changer. The mention of major players like $MRK, $LLY, and $BGNE as potential suitors adds a layer of strategic intrigue, especially with $GILD already holding a significant stake. A bidding war among these giants for a multi-billion-dollar opportunity is far from unrealistic. If clinical data continues to impress, $LPTX could see massive upside, both from market adoption and potential acquisition scenarios. SWE Cereno Scientific and $LPTX will be two game changers 2025. Exciting times ahead!

User Image Walter100 Posted - 1 day ago

$LPTX Without exaggeration, we have very good chances of capturing a lion’s share of the gastric/GEJ cancer space, because existing PD-1 inhibitor therapies either don’t work in all cases (work in only 1/3 cases) whereas DKN-01 can, And DKN-01 can improve treatment even in the 1/3rd cases because it improves effectiveness of PD-1 inhibitors. Multi-billion opportunity. $MRK $LLY $BGNE come to mind as interested suitors already playtime the gastric space. But $GILD has a 14% stake already in us. A competitive bidding scenario is not impossible. Excited how this will play out.

User Image Pika_Capital Posted - 1 day ago

$BGNE reentered - loaded bigly here.

User Image ThisIsBiotech Posted - 2 days ago

$MRK $LPTX $BGNE Great summary of the potential strategic fit for DKN-01 in the gastric cancer space! The differentiation of DKN-01 as PD-L1 'agnostic' indeed opens up opportunities to address unmet needs, especially for patients who aren't eligible for PD-1 inhibitors due to low PD-L1 expression. $MRK (Merck) and $BGNE (BeiGene) are certainly logical candidates for partnerships or acquisitions given their existing presence in the PD-1/PD-L1 space. The synergy with Keytruda and tislelizumab makes DKN-01 a strong contender to complement these therapies, especially with the increasing focus on personalized treatment strategies. It’ll be interesting to watch how Leap Therapeutics positions DKN-01 moving forward and whether the FDA’s criteria evolve to further highlight its unique capabilities in this patient population. Definitely one to keep on the radar!

User Image Walter100 Posted - 2 days ago

$LPTX If I’ve understood the technicalities correctly, FDA is putting restrictions based on PDL-1 expression measured by CPS scores on which patients are eligible for PD-1 inhibitors. Now, DKN-01 can address patients not eligible for PD-1 inhibitors due to low PD-L1 expression. (DKN-02 is PD-L1 ‘agnostic’). So, any company having only PD-1 inhibitors for gastric would be very interested in DKN-01. We’re talking about: $MRK : With Keytruda (pembrolizumab) in the gastric cancer space, Merck might seek DKN-01 to complement or enhance its portfolio, particularly if DKN-01 can address patients not eligible for PD-1 inhibitors due to low PD-L1 expression. $BGNE : Already involved with the DisTinGuish study through their PD-1 antibody tislelizumab, BeiGene would have a strategic interest in DKN-01 to broaden their offerings. Continued in reply post:

User Image Apr4609 Posted - 2 days ago

@Walter100 Furthermore, I doubt retailers at $BMY, $MRK, $BGNE care about gastric cancer (maybe beigene) but leap is about to show that adding dkn-01 to one of their pd-1 will make the other companies obsolete unless they add other products to their pd-1 Global reach and other collaborations with $gild and $roche are also in the background

User Image Fingerlickengood Posted - 5 days ago

$CHRS https://www.biospace.com/coherus-junshi-s-pd-1-blocker-loqtorzi-aces-phase-iii-liver-cancer-trial $PSFE $BGNE $AZN $INCY

User Image Fingerlickengood Posted - 5 days ago

$CHRS solid investment..cash in the bank! $AZN $PFE $BGNE $INCY https://www.lw.com/en/news/latham-watkins-advises-coherus-in-divesture-of-udenyca-franchise-to-intas-pharmaceuticals

User Image Fingerlickengood Posted - 1 week ago

$CHRS if speculation were permtted on this board, I’d speculate a buyout is coming! $BGNE but I don’t want the popo to fine me so I would NEVER speculate..it’s not ’helpful’ 🤣🤣🤣🤣https://tekinvestor.s3.dualstack.eu-west-1.amazonaws.com/original/3X/d/e/defca2bfb965feeeb0a7cbc0eb69962948d01bed.pdf

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE keep your eye on the prize! https://www.biospace.com/coherus-junshi-s-pd-1-blocker-loqtorzi-aces-phase-iii-liver-cancer-trial

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE https://www.youtube.com/watch?v=Ad6GqK5_4yU

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE look who's in my rear view again...the popo neofo! LMAO

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE This is interesting....BeiGene taking a $400M faculty loan in China ... could be nothing or could be something! I dunno...timing is interesting! https://media-beigene.todayir.com/20241210200801115211473134_en.pdf

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE I say M&A on the way! https://www.fiercepharma.com/marketing/say-goodbye-beigene-oncology-biopharma-becomes-beone-medicines

User Image G101SPM Posted - 1 week ago

#INSIDERS $AVDL Chief Executive Officer and two (2) Directors bought 33,279 Ordinary Shares combined at $9.80 - $10.19 worth approximately $330K. $NRDY Chief Executive Officer bought another 168,361 shares of Class A Common Stock at $1.52 - $1.60 worth approximately $266K. $UAMY Director bought 70,000 shares at $1.458 worth approximately $102K. $BGNE 10% owner Baker Bros. sold 1,037,017 American Depositary Shares worth more than $194 mln. $GTI Directors (2) sold 630,000 Class A Ordinary Shares combined worth approximately $1.4 mln.

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE moral of the story in a M&A, the dominate company stock falls!

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE I refer back to this and again ask the question 'why isn't Coherus named, and instead it explicitly states 'licensor'?' Leads me to believe, their may be a name change coming! https://www.yicaiglobal.com/bulletin/253000000376530653

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE Why would they sell so much stock prior to a mere name change? They just pulled $1B in revenue..... https://www.investing.com/news/insider-trading-news/beigene-directors-sell-shares-worth-1942-million-93CH-3765248

User Image Fingerlickengood Posted - 1 week ago

$CHRS $BGNE "he new name is part of a broader strategic growth plan that has enabled the Company’s global oncology leadership since its inception in 2010. The Company recently reported $1 billion in quarterly total revenue driven by strong growth in product revenue in the U.S. and Europe. To support its expansive clinical portfolio and global growth, the Company opened its $800 million flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July. Once the name is approved by shareholders, the company’s stock ticker on Nasdaq will change to “ONC”" https://www.businesswire.com/news/home/20241114671168/en/BeiGene-Unveils-Proposed-Name-Change-to-BeOne-Medicines-Reaffirming-Its-Mission-to-Unite-Global-Community-Against-Cancer

User Image Fingerlickengood Posted - 1 week ago

$CHRS BeiGene would fit as a potental buyer..CA based, works closely with Chinese clinical oncology companies, has the financial means…. .$BGNE

User Image Quantumup Posted - 1 week ago

H.C. Wainwright⬆️the PT on $NRIX to $35 was $30/Buy +⬆️NX-5948s probability of approval to 60% was 50%, after Nurix presented updated '5948🔬at #ASH24. HCW views NX-5948s ORR as highly favorable and relatively in-line with that seen for the $BGNE BTK degrader: $kymr $arvn

User Image OpenOutcrier Posted - 1 week ago

$BGNE (-4.4% pre) BeiGene’s Latest SEC Filing and Stock Exchange Updates - TR https://ooc.bz/l/50253

User Image vjtweet Posted - 1 week ago

$BGNE Giving it room to move, staggered stops, hang it there, going to make money.

User Image Walter100 Posted - 2 weeks ago

@cavsnut @Capitulation_0 $GILD 14% $BGNE 3.x%

User Image stockpicker63 Posted - 3 weeks ago

Stocks to watch next week! $BGNE, $CMCSA, $COHU and $IX.

User Image RhetroTX Posted - 11/28/24

$BGNE beautiful chart, primed for break out. Another Baker Bros play… that’s some smart money right there

User Image MaverikIT Posted - 11/27/24

@TheLongVol @IsabellaDC @net0trader @JaredSotken @Tommojg Eastern front$ $BGNE $FUTU $CWEB ... this damn doggy been barking loud DOGZ (spec)

User Image l4ndsh4rk Posted - 11/27/24

$BGNE $SRPT Nice moves, Sarepta back over the 200-day

Analyst Ratings
JMP Securities Market Outperform Sep 18, 24
JP Morgan Overweight Aug 20, 24
Citigroup Buy Aug 8, 24
B of A Securities Neutral Jul 9, 24
TD Cowen Buy May 9, 24
TD Cowen Buy Apr 24, 24
B of A Securities Neutral Apr 8, 24
Bernstein Market Perform Mar 27, 24
JP Morgan Overweight Mar 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lee Chan Henry SVP, General Counsel SVP, General Counsel Jul 31 Sell 216.2567 791 171,059 08/02/23
Wang Julia Aijun Chief Financial Offi.. Chief Financial Officer Jul 03 Sell 179.5495 472 84,747 07/06/23
Wang Lai Global Head of R&D Global Head of R&D Jun 26 Sell 182.53 1,108 202,243 06/27/23
Wang Julia Aijun Chief Financial Offi.. Chief Financial Officer Jun 23 Sell 182.85 840 153,594 06/27/23
Sanders Corazon (Corsee) D. Director Director Jun 23 Sell 181.7 578 105,023 06/27/23
Wu Xiaobin President, COO & GM.. President, COO & GM China Jun 26 Sell 182.365 1,495 272,636 06/27/23
Wang Lai Global Head of R&D Global Head of R&D Jun 15 Sell 192.42 1,325 254,956 06/20/23
HHLR ADVISORS, LTD. 10% Owner 10% Owner Jun 13 Sell 182.53 1,198,128 218,694,304 142,888,241 06/15/23
HHLR ADVISORS, LTD. 10% Owner 10% Owner Jun 08 Sell 182.05 2,956,689 538,265,232 144,086,369 06/12/23
Wang Lai Global Head of R&D Global Head of R&D Jun 07 Sell 224.67 462 103,798 06/09/23
Wu Xiaobin President, COO & GM.. President, COO & GM China Jun 07 Sell 224.67 3,291 739,389 06/09/23
Wang Xiaodong - - Mar 08 Option 0.13 67,635 8,793 67,635 03/10/23
Wang Xiaodong - - Mar 08 Sell 225.59 67,635 15,257,780 03/10/23
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Jan 10 Sell 248.72 20,391 5,071,650 01/12/23
Wang Xiaodong - - Jan 09 Sell 251.71 5,000 1,258,550 01/11/23
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Dec 27 Sell 224.64 9,609 2,158,566 12/29/22
Wang Xiaodong - - Dec 13 Sell 211.54 3,013 637,370 12/15/22
Wang Xiaodong - - Aug 05 Sell 195.1 16,060 3,133,306 08/09/22
Wang Julia Aijun Chief Financial Offi.. Chief Financial Officer Jul 01 Sell 158.50 317 50,244 07/18/22
Wang Lai Global Head of R&D Global Head of R&D Jun 27 Sell 177.3247 458 81,215 06/28/22
Wang Lai Global Head of R&D Global Head of R&D Jun 17 Sell 144.21 1,168 168,437 06/22/22
Wu Xiaobin President, COO & GM.. President, COO & GM China Jun 17 Sell 141.98 1,588 225,464 06/22/22
Wang Julia Aijun Chief Financial Offi.. Chief Financial Officer Jun 17 Sell 136.6393 161 21,999 06/21/22
Wang Lai Global Head of R&D Global Head of R&D Jun 06 Sell 141.9963 660 93,718 06/08/22
Wu Xiaobin President, COO & GM.. President, COO & GM China Jun 06 Sell 141.9946 3,410 484,202 06/08/22
Wu Xiaobin President, COO & GM.. President, COO & GM China May 05 Sell 165.7 6,725 1,114,332 05/06/22
Huang Jane CMO, Hematology CMO, Hematology Dec 14 Option 119.96 1,500 179,940 1,500 12/16/21
Huang Jane CMO, Hematology CMO, Hematology Dec 14 Sell 279.11 1,500 418,665 12/16/21
Huang Jane CMO, Hematology CMO, Hematology Nov 17 Option 119.96 1,500 179,940 1,500 11/19/21
Huang Jane CMO, Hematology CMO, Hematology Nov 17 Sell 381.37 1,500 572,055 11/19/21
Wang Xiaodong - - Nov 08 Sell 351.11 4,500 1,579,995 11/10/21
Huang Jane CMO, Hematology CMO, Hematology Oct 19 Option 119.96 1,500 179,940 1,500 10/21/21
Huang Jane CMO, Hematology CMO, Hematology Oct 19 Sell 372.39 1,500 558,585 10/21/21
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Sep 16 Sell 335.95 411,838 138,356,976 09/16/21
Huang Jane CMO, Hematology CMO, Hematology Sep 15 Sell 359.46 12,901 4,637,393 09/15/21
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Sep 02 Sell 282.71 288,639 81,601,132 09/02/21
Huang Jane CMO, Hematology CMO, Hematology Sep 02 Sell 318.86 1,087 346,601 09/02/21
Liang Howard CFO & Chief Strategy.. CFO & Chief Strategy Officer Jan 19 Option 6.5 14,000 91,000 12,600 01/19/21
Liang Howard CFO & Chief Strategy.. CFO & Chief Strategy Officer Jan 19 Sell 344.84 14,000 4,827,760 01/19/21
Liang Howard CFO & Chief Strategy.. CFO & Chief Strategy Officer Dec 16 Option 3.5 1,497,200 5,240,200 91,900 12/16/20
Liang Howard CFO & Chief Strategy.. CFO & Chief Strategy Officer Dec 16 Sell 228.58 91,900 21,006,502 12/16/20
Huang Jane CMO, Hematology CMO, Hematology Nov 02 Option 29.49 1,500 44,235 1,500 11/02/20
Huang Jane CMO, Hematology CMO, Hematology Nov 02 Sell 300.7 1,500 451,050 11/02/20
Huang Jane CMO, Hematology CMO, Hematology Oct 01 Option 29.49 1,500 44,235 1,500 10/01/20
Huang Jane CMO, Hematology CMO, Hematology Oct 01 Sell 280.16 1,500 420,240 10/01/20
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Sep 30 Sell 279.29 54,303 15,166,285 09/30/20
Wang Xiaodong - - Sep 21 Sell 260.69 5,000 1,303,450 09/21/20
OYLER JOHN Chief Executive Offi.. Chief Executive Officer Sep 16 Sell 253.52 81,228 20,592,923 09/16/20